Literature DB >> 34117325

Detection of significantly high vitreous concentrations of fatty acid-binding protein 4 in patients with proliferative diabetic retinopathy.

Kaku Itoh1, Masato Furuhashi2, Yosuke Ida1, Hiroshi Ohguro1, Megumi Watanabe1, Soma Suzuki1, Fumihito Hikage3.   

Abstract

The fatty acid-binding protein4 (FABP4) and vascular endothelial growth factor A (VEGFA) play key roles in the metabolic and cardiovascular diseases, and proliferative diabetic retinopathy (PDR), respectively. To identify FABP4 in vitreous fluid in PDR, vitreous concentrations of FABP4 (V-FABP4) and VEGFA (V-VEGFA) from PDR (n = 20) and non-PDR (n = 20) patients were determined by Enzyme-Linked ImmunoSorbent Assays. The data, which included height and weight, systemic blood pressures, several blood biochemical parameters and blood flow at the optic nerve head (ONH) by laser speckle flowgraphy (LSFG) were collected. The levels of V-FABP4 and V-VEGFA were significantly higher in PDR patients than in non-PDR patients (P < 0.001) with a high positive correlation (r = 0.72, P < 0.001) between them. The findings were not affected by body mass index values and the presence of vitreous hemorrhaging. Among the clinical parameters, V-FABP4 correlated positively with creatinine and negatively with age and aspartate transaminase (AST) levels, while V-VEGFA correlated positively with fasting plasma glucose and hemoglobin A1c (HbA1c) levels but negatively with AST. Multiple regression analyses indicated that V-VEGFA, or V-FABP4, AST and HbA1c were independent predictors of V-FABP4 or V-VEGFA, respectively. Both were negatively correlated, but more evident in V-FABP4, with the ONH ocular blood flow.

Entities:  

Year:  2021        PMID: 34117325     DOI: 10.1038/s41598-021-91857-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  39 in total

Review 1.  Diabetic Retinopathy.

Authors:  Andrew M Hendrick; Maria V Gibson; Ambar Kulshreshtha
Journal:  Prim Care       Date:  2015-09       Impact factor: 2.907

2.  Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome.

Authors:  Aimin Xu; Yu Wang; Jian Yu Xu; David Stejskal; Sidney Tam; Jialiang Zhang; Nelson M S Wat; Wai Keung Wong; Karen S L Lam
Journal:  Clin Chem       Date:  2006-01-19       Impact factor: 8.327

Review 3.  Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications.

Authors:  F Semeraro; F Morescalchi; A Cancarini; A Russo; S Rezzola; C Costagliola
Journal:  Diabetes Metab       Date:  2019-04-18       Impact factor: 6.041

4.  Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).

Authors:  João Figueira; Emily Fletcher; Pascale Massin; Rufino Silva; Francesco Bandello; Edoardo Midena; Monica Varano; Sobha Sivaprasad; Haralabos Eleftheriadis; Geeta Menon; Miguel Amaro; Sarah Ayello Scheer; Catherine Creuzot-Garcher; João Nascimento; Dalila Alves; Sandrina Nunes; Conceição Lobo; José Cunha-Vaz
Journal:  Ophthalmology       Date:  2018-02-01       Impact factor: 12.079

Review 5.  Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.

Authors:  Masato Furuhashi; Gökhan S Hotamisligil
Journal:  Nat Rev Drug Discov       Date:  2008-06       Impact factor: 84.694

Review 6.  Metabolic functions of FABPs--mechanisms and therapeutic implications.

Authors:  Gökhan S Hotamisligil; David A Bernlohr
Journal:  Nat Rev Endocrinol       Date:  2015-08-11       Impact factor: 43.330

7.  INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up.

Authors:  J Fernando Arevalo; Andres F Lasave; Lihteh Wu; Mauricio Maia; Manuel Diaz-Llopis; Arturo A Alezzandrini; Miguel Brito
Journal:  Retina       Date:  2017-02       Impact factor: 4.256

8.  Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation.

Authors:  Hideki Ota; Masato Furuhashi; Shutaro Ishimura; Masayuki Koyama; Yusuke Okazaki; Tomohiro Mita; Takahiro Fuseya; Tomohisa Yamashita; Marenao Tanaka; Hideaki Yoshida; Kazuaki Shimamoto; Tetsuji Miura
Journal:  Am J Hypertens       Date:  2012-06-21       Impact factor: 2.689

9.  Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population.

Authors:  Shutaro Ishimura; Masato Furuhashi; Yuki Watanabe; Kyoko Hoshina; Takahiro Fuseya; Tomohiro Mita; Yusuke Okazaki; Masayuki Koyama; Marenao Tanaka; Hiroshi Akasaka; Hirofumi Ohnishi; Hideaki Yoshida; Shigeyuki Saitoh; Tetsuji Miura
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

10.  Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy.

Authors:  Joonas Wirkkala; Risto Bloigu; Nina Maria Hautala
Journal:  BMJ Open Ophthalmol       Date:  2019-12-10
View more
  3 in total

1.  Fatty Acid-Binding Proteins 4 and 5 Are Involved in the Pathogenesis of Retinal Vascular Diseases in Different Manners.

Authors:  Megumi Higashide; Masato Furuhashi; Megumi Watanabe; Kaku Itoh; Soma Suzuki; Araya Umetsu; Yuri Tsugeno; Yosuke Ida; Fumihito Hikage; Hiroshi Ohguro
Journal:  Life (Basel)       Date:  2022-03-23

2.  Downregulation of fatty acid binding protein 4 alleviates lipid peroxidation and oxidative stress in diabetic retinopathy by regulating peroxisome proliferator-activated receptor γ-mediated ferroptosis.

Authors:  Xiao'e Fan; Manhong Xu; Qianfeng Ren; Yan Fan; Boshi Liu; Jiaqi Chen; Zhengmin Wang; Xiaoyan Sun
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  Fatty Acid-Binding Protein 4 in Patients with and without Diabetic Retinopathy.

Authors:  Ping Huang; Xiaoqin Zhao; Yi Sun; Xinlei Wang; Rong Ouyang; Yanqiu Jiang; Xiaoquan Zhang; Renyue Hu; Zhuqi Tang; Yunjuan Gu
Journal:  Diabetes Metab J       Date:  2022-04-28       Impact factor: 5.893

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.